Structured Review

Merck & Co glucophage
Effect of silibinin alone and in combination with <t>metformin</t> at the end of the study (Day 40) on ( A ) Serum total antioxidant capacity and ( B ) Tumor necrosis factor (TNF-α). Ordinary one-way ANOVA with Tukey’s multiple comparison was used. *p
Glucophage, supplied by Merck & Co, used in various techniques. Bioz Stars score: 88/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glucophage/product/Merck & Co
Average 88 stars, based on 12 article reviews
Price from $9.99 to $1999.99
glucophage - by Bioz Stars, 2022-11
88/100 stars

Images

1) Product Images from "Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities"

Article Title: Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities

Journal: Journal of Inflammation Research

doi: 10.2147/JIR.S379725

Effect of silibinin alone and in combination with metformin at the end of the study (Day 40) on ( A ) Serum total antioxidant capacity and ( B ) Tumor necrosis factor (TNF-α). Ordinary one-way ANOVA with Tukey’s multiple comparison was used. *p
Figure Legend Snippet: Effect of silibinin alone and in combination with metformin at the end of the study (Day 40) on ( A ) Serum total antioxidant capacity and ( B ) Tumor necrosis factor (TNF-α). Ordinary one-way ANOVA with Tukey’s multiple comparison was used. *p

Techniques Used:

Effect of silibinin alone and in combination with metformin on body weight during the study period. *Indicates significantly different versus baseline (control). Non-identical letters ( A – C ) indicate significant difference between different groups in different time points. Values represented as means ±SEM, number of animals per group =6. Two-way ANOVA with multiple comparison corrected by Tukey’s test was used.
Figure Legend Snippet: Effect of silibinin alone and in combination with metformin on body weight during the study period. *Indicates significantly different versus baseline (control). Non-identical letters ( A – C ) indicate significant difference between different groups in different time points. Values represented as means ±SEM, number of animals per group =6. Two-way ANOVA with multiple comparison corrected by Tukey’s test was used.

Techniques Used:

( A – F ) Estrous cycle changes in one most representative rat in each group during PCOS induction and treatment period. As reported by Myondo et al 29 ( A ) NC; negative control; ( B ) PC; positive control, received only distilled water after PCOS-induction; ( C ) Met 300mg/Kg received metformin 300mg/Kg after PCOS-induction; ( D – F ) received silibinin 100, 200mg/Kg and 100mg/Kg silibinin with 300mg/Kg metformin respectively after PCOS-induction.
Figure Legend Snippet: ( A – F ) Estrous cycle changes in one most representative rat in each group during PCOS induction and treatment period. As reported by Myondo et al 29 ( A ) NC; negative control; ( B ) PC; positive control, received only distilled water after PCOS-induction; ( C ) Met 300mg/Kg received metformin 300mg/Kg after PCOS-induction; ( D – F ) received silibinin 100, 200mg/Kg and 100mg/Kg silibinin with 300mg/Kg metformin respectively after PCOS-induction.

Techniques Used: Negative Control, Positive Control

2) Product Images from "Potential enhancement of metformin hydrochloride in solidified reverse micellar solution-based PEGylated lipid nanoparticles targeting therapeutic efficacy in diabetes treatment"

Article Title: Potential enhancement of metformin hydrochloride in solidified reverse micellar solution-based PEGylated lipid nanoparticles targeting therapeutic efficacy in diabetes treatment

Journal: Heliyon

doi: 10.1016/j.heliyon.2022.e09099

Combined particle size analysis result of the metformin-loaded beeswax-based non-PEGylated and PEGylated solid lipid nanoparticles.
Figure Legend Snippet: Combined particle size analysis result of the metformin-loaded beeswax-based non-PEGylated and PEGylated solid lipid nanoparticles.

Techniques Used: Particle Size Analysis

In vitro drug dissolution profile of metformin, metformin-loaded non-PEGylated and PEGylated beeswax-based SLNs.
Figure Legend Snippet: In vitro drug dissolution profile of metformin, metformin-loaded non-PEGylated and PEGylated beeswax-based SLNs.

Techniques Used: In Vitro

Representative of the morphology scanning electron micrograph, (SEM) of metformin-loaded PEGylated solid lipid nanoparticles (batch J 20 ).
Figure Legend Snippet: Representative of the morphology scanning electron micrograph, (SEM) of metformin-loaded PEGylated solid lipid nanoparticles (batch J 20 ).

Techniques Used:

Differential scanning calorimetry (DSC) thermogram of metformin-loaded lipid matrix (Drug-loaded LM 1 ).
Figure Legend Snippet: Differential scanning calorimetry (DSC) thermogram of metformin-loaded lipid matrix (Drug-loaded LM 1 ).

Techniques Used:

Differential scanning calorimetry (DSC) thermogram of metformin-loaded PEGylated lipid matrix (Drug-loaded PEG-LM 1 ).
Figure Legend Snippet: Differential scanning calorimetry (DSC) thermogram of metformin-loaded PEGylated lipid matrix (Drug-loaded PEG-LM 1 ).

Techniques Used:

Differential scanning calorimetry (DSC) thermogram of metformin.
Figure Legend Snippet: Differential scanning calorimetry (DSC) thermogram of metformin.

Techniques Used:

3) Product Images from "Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin "

Article Title: Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin

Journal: International Journal of Clinical Pharmacology and Therapeutics

doi: 10.5414/CP202197

Mean plasma concentration-time curve of metformin following a single oral administration of voglibose/metformin 0.2/500 mg fixed-dose combination (FDC) (open circle) vs. coadministered voglibose 0.2 mg and metformin 500 mg (closed circle) in 28 healthy subjects.
Figure Legend Snippet: Mean plasma concentration-time curve of metformin following a single oral administration of voglibose/metformin 0.2/500 mg fixed-dose combination (FDC) (open circle) vs. coadministered voglibose 0.2 mg and metformin 500 mg (closed circle) in 28 healthy subjects.

Techniques Used: Concentration Assay

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Merck & Co metformin
    Distress evaluation of an orthotopic pancreatic cancer model. Pancreatic cancer (PDA) was treated with α-cyano-4-hydroxycinnamate plus <t>metformin</t> (CHC/Met), Galloflavin plus Metformin (Gal/Met), or the respective vehicle solutions (V). Telemetric transmitters were implanted into mice in a separate experiment, and 6606PDA cells were injected into the pancreas (Tel + PDA). The percentage of body weight (A), the percentage of burrowing activity (B), nesting (C), and the distress score (D) were evaluated on the indicated days. Differences between the groups in (A) were assessed with the Kruskal-Wallis test. Significant differences in body weight between the groups were detected (χ 2 = 44.871, df = 4, p
    Metformin, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/metformin/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    metformin - by Bioz Stars, 2022-11
    90/100 stars
      Buy from Supplier

    88
    Merck & Co glucophage
    Effect of silibinin alone and in combination with <t>metformin</t> at the end of the study (Day 40) on ( A ) Serum total antioxidant capacity and ( B ) Tumor necrosis factor (TNF-α). Ordinary one-way ANOVA with Tukey’s multiple comparison was used. *p
    Glucophage, supplied by Merck & Co, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glucophage/product/Merck & Co
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glucophage - by Bioz Stars, 2022-11
    88/100 stars
      Buy from Supplier

    Image Search Results


    Distress evaluation of an orthotopic pancreatic cancer model. Pancreatic cancer (PDA) was treated with α-cyano-4-hydroxycinnamate plus metformin (CHC/Met), Galloflavin plus Metformin (Gal/Met), or the respective vehicle solutions (V). Telemetric transmitters were implanted into mice in a separate experiment, and 6606PDA cells were injected into the pancreas (Tel + PDA). The percentage of body weight (A), the percentage of burrowing activity (B), nesting (C), and the distress score (D) were evaluated on the indicated days. Differences between the groups in (A) were assessed with the Kruskal-Wallis test. Significant differences in body weight between the groups were detected (χ 2 = 44.871, df = 4, p

    Journal: bioRxiv

    Article Title: Robustness of a multivariate composite score when evaluating distress of animal models for gastrointestinal diseases

    doi: 10.1101/2022.11.14.516441

    Figure Lengend Snippet: Distress evaluation of an orthotopic pancreatic cancer model. Pancreatic cancer (PDA) was treated with α-cyano-4-hydroxycinnamate plus metformin (CHC/Met), Galloflavin plus Metformin (Gal/Met), or the respective vehicle solutions (V). Telemetric transmitters were implanted into mice in a separate experiment, and 6606PDA cells were injected into the pancreas (Tel + PDA). The percentage of body weight (A), the percentage of burrowing activity (B), nesting (C), and the distress score (D) were evaluated on the indicated days. Differences between the groups in (A) were assessed with the Kruskal-Wallis test. Significant differences in body weight between the groups were detected (χ 2 = 44.871, df = 4, p

    Article Snippet: Either α-cyano-4-hydroxycinnamate (CHC, daily i.p. injection of 15 mg/kg, Tocris Bioscience, Bristol, UK) plus metformin (Met, daily i.p. injection of 125 mg/kg, Merck, Darmstadt, Germany) or galloflavin (Gal, i.p. injection of 20 mg/kg three times a week, Tocris Bioscience) plus metformin (Met, daily i.p. injection of 125 mg/kg, Merck) were applied as chemotherapies until day 37 after cell injection (CHC/Met: n= 7, Gal/Met: n = 7).

    Techniques: Mouse Assay, Injection, Activity Assay

    LC–MS analyses of metabolic features and inhibitor sensitivity of papillary (ACHN) and clear cell renal cell carcinoma (786-O) cell lines. ( A ) LC–MS analysis of the intracellular metabolite concentrations in papillary (ACHN), clear cell (786-O) RCC and normal tubular epithelial (HK-2) cell lines. Lactate/pyruvate, pyruvate/citrate, and lactate/malate ratios were used to assess the glycolytic capacity and the activity of the TCA cycle of the cell lines (CIT–citrate, iCIT–isocitrate, α-KG–alpha-ketoglutarate, s-CoA–succinyl-CoA, SUC–succinate, FUM–fumarate, MAL–malate, OA–oxaloacetate), whereas lactate/glutamate ratio was used to evaluate the glutamine utilization. ( B ) The mTORC1 (rapamycin–rapa) and metabolic inhibitors (ACSS2i–inhibitor of acetate utilization, BPTES–glutaminolysis inhibitor, metformin–metf–AMPK-inhibitor, doxycycline–doxy–antibiotics with mitochondrial inhibitory effect) sensitivity of papillary (ACHN) and clear cell (786-O) RCC cell lines were evaluated as monotherapy or in combination. Regarding the 786-O cells, the treatments were performed both in RPMI-1640 (2000 mg/L glucose) medium under generally applied and optimized conditions and in DMEM high glucose (4500 mg/L)–to compare the role of maintaining parameters with similar glucose concentration levels as ACHN and HK-2 cells. * p values below 0.05, ** p values below 0.01 (one-way ANOVA with Tukey’s post hoc test), and at least 20% decrease in proliferation were considered biologically relevant. Synergistic treatment interactions were labeled with S (based on combination index calculation).

    Journal: International Journal of Molecular Sciences

    Article Title: Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics

    doi: 10.3390/ijms231810587

    Figure Lengend Snippet: LC–MS analyses of metabolic features and inhibitor sensitivity of papillary (ACHN) and clear cell renal cell carcinoma (786-O) cell lines. ( A ) LC–MS analysis of the intracellular metabolite concentrations in papillary (ACHN), clear cell (786-O) RCC and normal tubular epithelial (HK-2) cell lines. Lactate/pyruvate, pyruvate/citrate, and lactate/malate ratios were used to assess the glycolytic capacity and the activity of the TCA cycle of the cell lines (CIT–citrate, iCIT–isocitrate, α-KG–alpha-ketoglutarate, s-CoA–succinyl-CoA, SUC–succinate, FUM–fumarate, MAL–malate, OA–oxaloacetate), whereas lactate/glutamate ratio was used to evaluate the glutamine utilization. ( B ) The mTORC1 (rapamycin–rapa) and metabolic inhibitors (ACSS2i–inhibitor of acetate utilization, BPTES–glutaminolysis inhibitor, metformin–metf–AMPK-inhibitor, doxycycline–doxy–antibiotics with mitochondrial inhibitory effect) sensitivity of papillary (ACHN) and clear cell (786-O) RCC cell lines were evaluated as monotherapy or in combination. Regarding the 786-O cells, the treatments were performed both in RPMI-1640 (2000 mg/L glucose) medium under generally applied and optimized conditions and in DMEM high glucose (4500 mg/L)–to compare the role of maintaining parameters with similar glucose concentration levels as ACHN and HK-2 cells. * p values below 0.05, ** p values below 0.01 (one-way ANOVA with Tukey’s post hoc test), and at least 20% decrease in proliferation were considered biologically relevant. Synergistic treatment interactions were labeled with S (based on combination index calculation).

    Article Snippet: The mTORC1 inhibitor rapamycin (50 ng/mL, Merck–Sigma-Aldrich), acyl-coenzyme A synthetase short-chain family member 2 (ACSS2) inhibitor (15 µM, Selleckchem Chemicals, Houston, TX, USA), bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)-ethyl sulfide (BPTES) (5 µM, Merck–Sigma-Aldrich) GLS inhibitor, metformin (300 µM, Merck–Sigma-Aldrich) OXPHOS inhibitor and doxycycline (10 µM, Merck–Sigma-Aldrich) mitochondrial function inhibitory antibiotic were added as monotherapy and in combination with rapamycin for 72 h. Inhibitor concentrations were determined based on our previous studies and other publications [ , , , ].

    Techniques: Liquid Chromatography with Mass Spectroscopy, Activity Assay, Concentration Assay, Labeling

    Effect of silibinin alone and in combination with metformin at the end of the study (Day 40) on ( A ) Serum total antioxidant capacity and ( B ) Tumor necrosis factor (TNF-α). Ordinary one-way ANOVA with Tukey’s multiple comparison was used. *p

    Journal: Journal of Inflammation Research

    Article Title: Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities

    doi: 10.2147/JIR.S379725

    Figure Lengend Snippet: Effect of silibinin alone and in combination with metformin at the end of the study (Day 40) on ( A ) Serum total antioxidant capacity and ( B ) Tumor necrosis factor (TNF-α). Ordinary one-way ANOVA with Tukey’s multiple comparison was used. *p

    Article Snippet: Letrozole was obtained from DENK PHARMA GmbH-Germany, Metformin which was commercially available as Glucophage from Merck Sante, Germany.

    Techniques:

    Effect of silibinin alone and in combination with metformin on body weight during the study period. *Indicates significantly different versus baseline (control). Non-identical letters ( A – C ) indicate significant difference between different groups in different time points. Values represented as means ±SEM, number of animals per group =6. Two-way ANOVA with multiple comparison corrected by Tukey’s test was used.

    Journal: Journal of Inflammation Research

    Article Title: Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities

    doi: 10.2147/JIR.S379725

    Figure Lengend Snippet: Effect of silibinin alone and in combination with metformin on body weight during the study period. *Indicates significantly different versus baseline (control). Non-identical letters ( A – C ) indicate significant difference between different groups in different time points. Values represented as means ±SEM, number of animals per group =6. Two-way ANOVA with multiple comparison corrected by Tukey’s test was used.

    Article Snippet: Letrozole was obtained from DENK PHARMA GmbH-Germany, Metformin which was commercially available as Glucophage from Merck Sante, Germany.

    Techniques:

    ( A – F ) Estrous cycle changes in one most representative rat in each group during PCOS induction and treatment period. As reported by Myondo et al 29 ( A ) NC; negative control; ( B ) PC; positive control, received only distilled water after PCOS-induction; ( C ) Met 300mg/Kg received metformin 300mg/Kg after PCOS-induction; ( D – F ) received silibinin 100, 200mg/Kg and 100mg/Kg silibinin with 300mg/Kg metformin respectively after PCOS-induction.

    Journal: Journal of Inflammation Research

    Article Title: Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities

    doi: 10.2147/JIR.S379725

    Figure Lengend Snippet: ( A – F ) Estrous cycle changes in one most representative rat in each group during PCOS induction and treatment period. As reported by Myondo et al 29 ( A ) NC; negative control; ( B ) PC; positive control, received only distilled water after PCOS-induction; ( C ) Met 300mg/Kg received metformin 300mg/Kg after PCOS-induction; ( D – F ) received silibinin 100, 200mg/Kg and 100mg/Kg silibinin with 300mg/Kg metformin respectively after PCOS-induction.

    Article Snippet: Letrozole was obtained from DENK PHARMA GmbH-Germany, Metformin which was commercially available as Glucophage from Merck Sante, Germany.

    Techniques: Negative Control, Positive Control